Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$2.83 USD
-0.09 (-3.08%)
Updated Aug 6, 2025 09:46 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LSTA 2.83 -0.09(-3.08%)
Will LSTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LSTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LSTA
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
LSTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
Other News for LSTA
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business ...
12 Health Care Stocks Moving In Monday's Pre-Market Session
LSTA Shows Promising Results in Latest iLSTA Trial | LSTA Stock News
Lisata Therapeutics (LSTA) Completes Enrollment for Pancreatic Cancer Trial | LSTA Stock News
Lisata Therapeutics, WARPNINE announce iLSTA trial enrollment completion